Investigations of Statins in Heart Failure: Inflammatory Biomarkers and Hormones

Kjekshus, 1997, The effects of simvastatin on the incidence of heart failure in patients with coronary artery disease, J Card Fail, 3, 249, 10.1016/S1071-9164(97)90022-1 Horwich, 2004, Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure, J Am Coll Cardiol, 43, 642, 10.1016/j.jacc.2003.07.049 Hognestad, 2004, Effect of combined statin and beta blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure, Am J Cardiol, 93, 603, 10.1016/j.amjcard.2003.11.027 Mozaffarian, 2004, Statin therapy is associated with lower mortality among patients with severe heart failure, Am J Cardiol, 93, 1124, 10.1016/j.amjcard.2004.01.039 Node, 2003, Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy, Circulation, 108, 839, 10.1161/01.CIR.0000084539.58092.DE Laufs, 2004, Beneficial effects of statins in patients with non-ischemic heart failure, Z Kardiol, 93, 103, 10.1007/s00392-004-1005-0 Tousoulis, 2005, Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure, Atherosclerosis, 178, 359, 10.1016/j.atherosclerosis.2004.08.037 Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 1, 10.1056/NEJMoa0706201 Follath, 1999, Nonischemic heart failure: epidemiology, pathophysiology, and progression of disease, J Cardiovasc Pharmacol, 33, S31 Mann, 2002, Inflammatory mediators and the failing heart: past, present, and the foreseeable future, Circ Res, 91, 988, 10.1161/01.RES.0000043825.01705.1B von Huehling, 2004, Tumor necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications, Basic Res Cardiol, 99, 18, 10.1007/s00395-003-0433-8 Anker, 1997, Wasting as independent risk factor for mortality in chronic heart failure, Lancet, 349, 1050, 10.1016/S0140-6736(96)07015-8 Rauschhaus, 2000, Plasma cytokine parameters and mortality in patients with heart failure, Circulation, 102, 3060, 10.1161/01.CIR.102.25.3060 Deswal, 2001, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST), Circulation, 103, 2055, 10.1161/01.CIR.103.16.2055 Kaneko, 1999, C-reactive protein in dilated cardiomyopathy, Cardiology, 91, 215, 10.1159/000006913 Curtis, 2002, Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight, Mayo Clin Proc, 77, 45, 10.4065/77.1.45 Parati, 1995, Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation: a critical appraisal, Hypertension, 25, 1276, 10.1161/01.HYP.25.6.1276 Cohn, 1993, Mechanistic data from the VA cooperative studies: ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmia, and plasma norepinephrine as determinants of prognosis in heart failure, Circulation, 86, V15 Pliquett, 2003, Simvastatin normalizes autonomic neural control in heart failure, Circulation, 107, 2493, 10.1161/01.CIR.0000065606.63163.B9 Ramasubbu, 2006, The emerging role of statins in the treatment of heart failure, J Am Coll Cardiol, 47, 342, 10.1016/j.jacc.2005.10.031 Koh, 2000, Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability, Cardiovasc Res, 47, 648, 10.1016/S0008-6363(00)00146-2 Lefer, 2002, Statins as potent anti-inflammatory drugs, Circulation, 106, 2041, 10.1161/01.CIR.0000033635.42612.88 Hayashidani, 2002, Fluvastatin attenuates left ventricular remodeling and failure after myocardial infarction, Circulation, 105, 868, 10.1161/hc0702.104164 Jain, 2005, Anti-inflammatory effects of statins: clinical evidence and basic mechanisms, Nat Rev Drug Discov, 4, 977, 10.1038/nrd1901 Lipinski, 2007, Drug insight: statins for nonischemic heart failure. Evidence and potential mechanisms, Nat Clin Pract Cardiovasc Med, 4, 196, 10.1038/ncpcardio0855 Ridker, 2001, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, 344, 1959, 10.1056/NEJM200106283442601 Rauschhaus, 2003, The relationship between cholesterol and survival in patients with chronic heart failure, J Am Coll Cardiol, 42, 1933, 10.1016/j.jacc.2003.07.016 Richartz, 1998, Low serum cholesterol levels predict high perioperative mortality in patients supported by a left ventricular assist system, Cardiology, 89, 184, 10.1159/000006785 Horwich, 2002, Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure, J Cardiac Failure, 8, 216, 10.1054/jcaf.2002.0804216 Rauschhaus, 2000, The endotoxin-lipoprotein hypothesis, Lancet, 356, 930, 10.1016/S0140-6736(00)02690-8 Marz, 2000, Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy, J Cardiovasc Pharmacol Ther, 5, 275, 10.1054/JCPT.2000.16695 Bleske, 2001, The effect of pravastatin and atorvastatin on coenzyme Q10, Am Heart J, 142, 262, 10.1067/mhj.2001.116762 Berthold, 2006, Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial, Drug Saf, 29, 703, 10.2165/00002018-200629080-00007 Strey, 2005, Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure, Atherosclerosis, 179, 201, 10.1016/j.atherosclerosis.2004.10.009 Sander, 2006, The impact of coenzyme Q10 on systolic function in patients with chronic heart failure, J Card Fail, 12, 464, 10.1016/j.cardfail.2006.03.007 Stewart, 2005, Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Investigators: white blood cell count predicts reduction in coronary heart disease mortality with pravastatin, Circulation, 111, 1756, 10.1161/01.CIR.0000160924.73417.26 Lipinski, 2006, Effect of statins and white blood cell count on mortality in patients with ischemic left ventricular dysfunction undergoing percutaneous coronary intervention, Clin Cardiol, 29, 36, 10.1002/clc.4960290109 Sola, 2005, Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory makers in patients with heart failure, J Card Fail, 11, 607, 10.1016/j.cardfail.2005.05.011 Sola, 2006, Atorvastatin improves left ventricular systolic function in nonischemic heart failure, J Am Coll Cardiol, 47, 332, 10.1016/j.jacc.2005.06.088 Wojnicz, 2006, Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels, Am J Cardiol, 97, 899, 10.1016/j.amjcard.2005.09.142 Anker, 1999, Insights into the pathogenesis of heart failure: immune activation and cachexia, Curr Opin Cardiol, 14, 211, 10.1097/00001573-199905000-00004 Bleske, 2006, Neutral effects of markers of heart failure, inflammation, endothelial activation and function, and vagal tone following HMG-CoA reductase inhibition in non-diabetic cardiomyopathy and average low-density lipoprotein level, J Am Coll Cardiol, 47, 338, 10.1016/j.jacc.2005.06.087 Sosnowski, 2004, Use of statins in heart failure, European Journal of Cardiology Practice, 3, 28 Kjekshus, 2005, CORONA: controlled rosuvastatin multinational study in heart failure, Eur J Heart Fail, 7, 1059, 10.1016/j.ejheart.2005.09.005 Tavazzi, 2004, Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure, Eur J Heart Fail, 6, 635, 10.1016/j.ejheart.2004.03.001